Skip to main content
Equibles
VERA logo

VERA · Vera Therapeutics, Inc.

Track VERA — free

Use VERA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VERA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$35.05 +1.45 (+4.32%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.47B
Shares
72.06M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$35.05 Open$33.91 Day$33.75–35.29 52W close$23.77–55.67 Avg vol 30d2.1M Short int19.9M · 27.6% float · 10.8d Short vol54% Last earningsNov 5, 2025 DataMay 2021–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$401.89M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-13.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$423.93M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.6%
Year over year · more shares
Price change (1Y)
+37.9%
Trailing year
Short interest
27.6%
Latest settlement · 10.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −0%
below
RSI (14) 53
neutral
MACD trend Positive
52-week position 35%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +21%
trailing
6-month return −14%
trailing
YTD return −31%
this year
Relative strength −31%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $35 › 200d $40 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
27.58% of float · ▲ +18.2% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
221 holders — mid 3-yr range
Squeeze score 83
high risk · 0–100
Fundamentals
Weak
EPS growth −69%
Y/Y
Free cash flow $-241.7M
Balance sheet $279.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 60%
annualized · 1-yr
Max drawdown −48%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−0% Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
35% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $35 › 200d $40 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
27.58% of float · ▲ +18.2% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
221 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $24 Now $35 · 35% Range high $56
vs 200-day avg -11% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VERA
Vera Therapeutics, Inc.
this stock
$2.47B -30.8% — — 27.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
221
% held
108.7%
Net QoQ
+5.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
211
View
Short & Settlement
Short Interest Rising
Shares short
19.9M
Days to cover
10.8d
Change
+3.1M sh
View
Short Volume
Short vol %
54%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
977
Value
$28.2K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
47.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-299.6M
EPS diluted
$-4.66
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
12
View
Proposed Sales
Value
$2.2M
Shares
64.8K
Filed
Sep 2, 2026
View
Exempt Offerings
Offering
$70.7M
Filed
Feb 25, 2021
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 15, 2026
Last call
Sep 10, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
VERA +0.2% +21.3% -13.5% +2.9% -30.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +1.3% +23.1% -31.4% +3.2% -42.9%
Key facts CIK 1831828 CUSIP 92337R101 13F (30d) 132 filings 132 filers Visit website Investor relations